journal
MENU ▼
Read by QxMD icon Read
search

Endocrine Practice

journal
https://www.readbyqxmd.com/read/30383500/a-2017-survey-of-the-clinical-practice-patterns-in-the-management-of-relapsing-graves-disease
#1
Shlomit Koren, Miriam Shteinshnaider, Karen Or, Dror Cantrell, Carlos A Benbassat, Ronit Koren
OBJECTIVE: Previous surveys from different world regions have demonstrated variations in the clinical management of Graves' disease (GD). We aim to investigate the clinical approach to GD relapse among endocrinologists. METHODS: Electronic questionnaires were e-mailed to all members of the Israeli Endocrine Society. Questionnaires included demographic data and different scenarios regarding treatment and follow up of patients with GD relapse. RESULTS: The response rate was 49...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383499/initial-adoption-of-recombinant-human-thyroid-stimulating-hormone-following-thyroidectomy-in-the-medicare-thyroid-cancer-patient-population
#2
Michaela A Dinan, Yanhong Li, Shelby D Reed, Julie Ann Sosa
OBJECTIVE: Recombinant human thyrotropin (rhTSH) has been approved for diagnostic (1998) and therapeutic (2008) indications in conjunction with radioactive iodine (RAI) administration post-thyroidectomy. Potential benefits of rhTSH, including avoidance of hypothyroidism side effects and shorter, less costly hospital stays, have not been assessed at the population level within the United States. In this study we quantify utilization, outcomes, and associated costs of rhTSH within the nationally representative SEER-Medicare patient population...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383498/sudden-bilateral-adrenal-hypertrophy
#3
Run Yu
No abstract text is available yet for this article.
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383497/statistical-comparison-of-afirma-gsc-and-afirma-gec-outcomes-in-a-community-endocrine-surgical-practice-early-findings
#4
R Mack Harrell, Stephanie A Eyerly-Webb, Allan C Golding, Courtney M Edwards, David N Bimston
OBJECTIVE: The Veracyte Afirma Gene Expression Classifier (GEC) has been the most widely used negative predictive value molecular classifier for indeterminate cytology thyroid nodule aspirates (FNA's) since 1/2011. To improve specificity and further reduce unnecessary thyroid surgeries, a second generation assay (Afirma GSC) was released for clinical use in 8/2017. We report 11 months of clinical outcomes experience with the GSC and compare them to our 6.5 year experience with the GEC...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383496/thyroid-nodule-location-on-ultrasonography-as-a-predictor-of-malignancy
#5
Fan Zhang, Oluwaseun Oluwo, Fiorella Beatriz Castillo, Gangula, Matthew Castillo, Fady Farag, Sibai Zakaria, Tooraj Zahedi
OBJECTIVE: The diagnostic capacity of ultrasonography (US) for differentiating between malignant and benign thyroid nodules is crucial in preventing unnecessary invasive procedures. This is the first study to evaluate whether thyroid nodule location on ultrasonography (US) has predictive value for malignancy. METHODS: We retrospectively reviewed data from 219 patients with thyroid nodules who underwent fine-needle aspiration (FNA) biopsy in one year. Patients' demographics as well as nodule's laterality, polarity, morphology and multinodularity were analyzed...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383495/efficacy-and-safety-of-ideglira-in-older-patients-with-type-2-diabetes
#6
Ildiko Lingvay, Yehuda Handelsman, Sultan Linjawi, Tina Vilsbøll, Natalie Halladin, Kristina Ranc, Andreas Liebl
Objective The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, two-arm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged <65 and 87 patients aged ≥65 years from DUAL II, 326 patients <65 years and 112 patients ≥65 years from DUAL III, and 412 patients <65 years and 145 patients ≥65 years from DUAL V...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383494/is-it-worth-suppressing-tsh-in-low-and-intermediate-risk-papillary-thyroid-cancer-patients-before-the-first-disease-assessment
#7
Lamartina Livia, Montesano Teresa, Falcone Rosa, Biffoni Marco, Grani Giorgio, Maranghi Marianna, Ciotti Laura, Giacomelli Laura, Ramundo Valeria, Lo Monaco Cristiano, Di Gioia Cira Rosaria, Lucia Peirnatale, Ronga Giuseppe, Durante Cosimo
Objective Guidelines recommend TSH suppression before the first response to treatment assessment in papillary thyroid cancer (PTC) patients. The aim of this study was to assess the rate of structural disease (SD) in low- and intermediate-risk PTC patients according to TSH levels measured 1 year after primary treatment. Methods A consecutive, prospective series of low- and intermediate-risk PTC patients with 3-years follow-up was collected. TSH, thyroglobulin, anti-thyroglobulin antibodies, and neck ultrasonography 1 and 3 years after primary treatment were analyzed...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383493/challenges-of-securing-growth-hormone-coverage-for-idiopathic-short-stature-review-of-the-7-year-experience-at-one-institution
#8
Marie Christianne Sandhya Ravi Chandar, Paul B Kaplowitz, Priya Vaidyanathan
BACKGROUND: Despite FDA approval of growth hormone(GH) for idiopathic short stature(ISS), many providers face challenges obtaining insurance coverage. We reviewed the insurance coverage experience for ISS at our hospital to identify factors predictive of approval or denial. METHODS: We reviewed charts of patients who underwent GH stimulation testing from 07/01/09 to 04/30/17 to identify ISS patients (height <-2.25SD, subnormal predicted adult height(PAH) and peak GH >10ng/ml) Results: 87 patients met ISS criteria, of whom 47(29M/18F) had GH request submitted to insurance...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383492/thyroid-cancer-incidence-continues-to-rise-but-mortality-remains-stable-in-young-hispanic-and-black-populations-in-the-united-states
#9
Anupam Kotwal, Archie Bleyer, Juan P Brito
No abstract text is available yet for this article.
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383491/improving-after-hours-calls-to-endocrinology-fellows
#10
Uzma Mohammad Siddiqui, Sanaa Ayyoub, Sobia Raja, Shamima Yeasmin, David M Harlan, Neil Aronin, Mira S Torres
OBJECTIVE: To analyze the frequency and nature of after-hours calls to Endocrinology Fellows and employ interventions to direct appropriate care to Primary endocrinologists. METHODS: The On Call Fellows logged calls that came to them during the after-hours and marked them as 'urgent or non-urgent'. We analyzed these calls and then implemented interventions to educate patients on calls that can wait until next business day. We also trained providers to provide script refills during clinic visits and educated Fellows on how to best manage and document these after-hours calls...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383490/efficacy-and-safety-of-bisphosphonate-therapy-in-mccune-albright-syndrome-related-polyostotic-fibrous-dysplasia-a-single-center-experience
#11
Yabing Wang, Ou Wang, Yan Jiang, Mei Li, Weibo Xia, Xunwu Meng, Xiaoping Xing
OBJECTIVE: Fibrous dysplasia (FD) is a rare disorder characterized by pain, deformity, and pathological fractures. McCune-Albright syndrome (MAS) includes a combination of FD, hyperfunctional endocrinopathy, and/or café-au-lait pigmentation. Surgery is generally ineffective in treating FD. This study aims to evaluate the efficacy and safety of bisphosphonates (BPs), and to compare the efficacy of different bisphosphonates in FD patients. METHODS: In this retrospective clinical study, laboratory and clinical findings of 22 polyostotic FD cases all associated with MAS were recorded before and after therapy with BPs...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383489/cheiroarthropathy-a-common-disorder-in-patients-in-the-t1d-exchange
#12
Grazia Aleppo, Lauren G Kanapka, Nicole C Foster, Mengdi Wu, Mark A Clements, Michael R Rickels, Janet B McGill, Roy W Beck
BACKGROUND: Diabetic cheiroarthropathy is a long-term complication of diabetes that causes significant morbidity and can impair functional abilities. It has not been well studied in individuals with type 1 diabetes (T1D). The T1D Exchange registry provided an opportunity to assess the frequency of cheiroarthropathy and related characteristics. MATERIALS AND METHODS: An internet-based survey was sent to 6,199 registry participants >18 years old, with 1,911 (31%) responding (62% female, 90% non-Hispanic White, mean age 40 yrs, median diabetes duration 20 yrs, mean HbA1c 7...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383488/commentary-on-management-of-osteoporosis-in-advanced-ckd-common-view-of-a-nephrologist-and-a-bone-specialist
#13
Ludmila Brunerova, Vladimir Palicka, Sylvie Dusilova Sulkova
No abstract text is available yet for this article.
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383487/disease-presentation-and-remission-rate-in-graves-disease-treated-with-anti-thyroid-drugs-is-gender-really-a-factor
#14
Talia Diker-Cohen, Hadar Duskin-Bitan, Ilan Shimon, Dania Hirsch, Amit Akirov, Gloria Tsvetov, Eyal Robenshtok
OBJECTIVE: Male gender is considered an adverse prognostic factor for remission of Graves' disease treatment with anti-thyroid drugs (ATD), though published data is conflicting. This often results in early consideration of radioiodine treatment and surgery for men. Our objective was to compare disease presentation and outcome in men versus women treated with ATDs. METHODS: Retrospective study of 235 patients (64 men, 171 women) with Graves' disease who were evaluated for features at presentation and outcome at the end of follow-up between 2010 and 2015...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383486/a-prospective-study-of-commonly-utilized-regimens-of-vitamin-d-replacement-and-maintenance-therapy-in-adults
#15
Daniel C Rafii, Farah Ali, Amal Farag, Bhanu Iyer, Philip E Otterbeck, Ronak Chaudhari, Natia Potter, Dimitre G Stefanov, Helena A Guber
OBJECTIVE: To determine which vitamin D dose, formulation and schedule most effectively and safely achieved a 25-hydroxy vitamin D (25OHD) level of > 30 ng/mL (75 nmol/L). METHODS: In this prospective study, 100 subjects from the NY Harbor HCS Brooklyn Campus, ages 25-85 years old, with 25OHD <30 ng/mL (<75 nmol/L), were randomized into 4 groups: cholecalciferol (D3) 2,000 IU daily, D3 3,000 IU daily, ergocalciferol (D2) 50,000 IU weekly and D2 50,000 IU twice weekly...
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30383485/the-circle-of-care-in-diabetes-from-home-to-hospital-to-home
#16
M Cecilia Lansang
No abstract text is available yet for this article.
November 1, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30289315/regulation-of-free-fatty-acids-by-sitagliptin-monotherapy-in-drug-na%C3%A3-ve-subjects-with-type-2-diabetes
#17
Eiji Kutoh, Asuka Wada, Jyunka Hayashi
OBJECTIVES: The aim of this study is to investigate the effects of sitagliptin on the regulation of FFA and other metabolic parameters in drug-naïve subjects with T2DM. SUBJECTS AND METHODS: This is a prospective, non-randomized, observational study. Drug naïve subjects with T2DM received 25-50 mg/day sitagliptin monotherapy (n=64). At 3 months, FFA and other metabolic parameters were compared with those at baseline. FFA was measured by colorimetry with enzymatic reactions...
October 5, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30289314/making-a-difference-in-adrenal-fatigue
#18
Rashmi S Mullur
No abstract text is available yet for this article.
October 5, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30289313/calcium-creatinine-clearance-ratio-is-not-helpful-in-differentiating-primary-hyperparathyroidism-from-familial-herpercalcemic-hypocalciuria-a-study-of-1000-patients
#19
Edwina C Moore, Eren Berber, Judy Jin, Vikram Krishnamurthy, Joyce Shin, Allan Siperstein
OBJECTIVE: With increasing recognition of more subtle presentations of primary hyperparathyroidism (pHPT), laboratory values are frequently seen in a range that would be expected for patients who have familial hypercalcemic hypocalciuria (FHH). Calcium creatinine clearance ratio (CCCR) has been advocated as a diagnostic tool to differentiate between these two disorders. However, it is limited by an indeterminate range (0.01-0.02). The aim of this study is to assess the relevance of CCCR in a modern series of patients with surgically managed pHPT...
October 5, 2018: Endocrine Practice
https://www.readbyqxmd.com/read/30289312/gut-and-bone-connection-celiac-disease-presented-as-hypertrophic-osteoarthropathy
#20
Darin Ruanpeng, Tasma Harindhanavudhi
No abstract text is available yet for this article.
October 5, 2018: Endocrine Practice
journal
journal
32527
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"